A Diabetes Outcomes Progression Trial
Contact us
Phone: +44 (0)1865 857240
Email: dtu@dtu.ox.ac.uk
OVERVIEW
ADOPT was a pragmatic, real-life, double-blind, randomised multicentre study which was evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT was designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT provided data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes.
RESULTS
The ADOPT results were announced at the IDF 19th World Diabetes Congress in Cape Town on Monday 4th December at 16.30 local time and simultaneously published in the New England Journal of Medicine.
ADOPT PUBLICATIONS
-
Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
1 May 2011
-
Effects Of Rosiglitazone, Glyburide, and Metformin on beta-Cell Function and Insulin Sensitivity in ADOPT
1 May 2011
-
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
1 January 2010
-
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)
1 January 2010
-
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
7 December 2006
-
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
1 December 2006
-
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
1 August 2006
-
Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe
1 December 2004
-
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
1 October 2002
ADOPT Conference Abstracts
-
Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial) [43rd Annual Meeting of the European Association for the Study of Diabetes]
1 January 2007
-
Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain [43rd Annual Meeting of the European Association for the Study of Diabetes]
1 January 2007
-
Determinants of monotherapy failure in ADOPT (A Diabetes Outcome Progression Trial) [43rd Annual Meeting of the European Association for the Study of Diabetes]
1 January 2007
-
ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes [43rd Annual Meeting of the European Association for the Study of Diabetes]
1 January 2007
-
Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in recently diagnosed, drug-naive type 2 diabetes: the ADOPT study cohort [41st Annual Meeting of the European Association for the Study of Diabetes]
1 January 2005
-
BMI and ratio of triglycerides to HDL are most predictive of insulin resistance in a drug naive population with type 2 diabetes [41st Annual Meeting of the European Association for the Study of Diabetes]
1 January 2005
-
Hepatic enzymes are associated with insulin resistance and impaired fibrinolysis in drug naïve, recently diagnosed type 2 diabetes subjects [65th Scientific Sessions of the American Diabetes Association]
1 January 2005
-
Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in type 2 diabetes [65th Scientific Sessions of the American Diabetes Association]
1 January 2005
-
Estimations of the clinical benefit of optimal blood glucose, blood pressure and lipid control in type 2 diabetic patients with the metabolic syndrome [18th International Diabetes Federation Congress]
1 January 2003
-
Differences in the prevalence of the metabolic syndrome between ethnic groups in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study [18th International Diabetes Federation Congress]
1 January 2003
-
Symptoms and health status in a recently-diagnosed type 2 diabetic population: the ADOPT study [18th International Diabetes Federation Congress]
1 January 2003
-
Are different clinical practice guidelines associated with regional differences in diabetes care? [18th International Diabetes Federation Congress]
1 January 2003
-
Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort. [18th International Diabetes Federation Congress]
1 January 2003
-
Prevalence of microalbuminuria in recently diagnosed type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study [18th International Diabetes Federation Congress]
1 January 2003
-
Lack of concordance of WHO and NCEP criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort [18th International Diabetes Federation Congress]
1 January 2003
-
Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study [18th International Diabetes Federation Congress]
1 January 2003
-
Ethnic differences in the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study [63rd Scientific Sessions of the American Diabetes Association]
1 January 2003
-
Lack of concordance of NCEP and WHO criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort [63rd Scientific Sessions of the American Diabetes Association]
1 January 2003
-
Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT study [63rd Scientific Sessions of the American Diabetes Association]
1 January 2003
-
Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort [63rd Scientific Sessions of the American Diabetes Association]
1 January 2003